Aquestive Therapeutics vs Fortress Biotech
AQST and FBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and FBIO compare
Aquestive Therapeutics is the larger company, worth 6.9 times as much as Fortress Biotech ($464M against $66.9M).
Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus 15.5% for Fortress Biotech).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −145% at Aquestive Therapeutics.
Fortress Biotech scores higher on the StockData Score (9 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | FBIO |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $66.9M |
| Share price | $3.70 | $1.82 |
| Change, 1 year | −31.4% | −30.5% |
| Change, 5 years | −41.9% | −95.7% |
| Beta (5Y) | 1.20 | 0.64 |
| Employees | 147 | 78 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.6× | 1.0× (better) |
| P/B | – | 0.4× |
| FCF yield | −9.9% | – |
| Growth | ||
| Revenue growth (TTM) | 22.6% (better) | 15.5% |
| Revenue growth, 5Y average | −0.58% | 6.8% (better) |
| Profitability | ||
| Gross margin | 67.0% (better) | 65.6% |
| Operating margin | −97.5% | −42.9% (better) |
| Net margin | −145% | 163% (better) |
| FCF margin | −85.0% | – |
| Return on equity | – | 107% |
| Return on invested capital | – | −261% |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Interest coverage | −4.7× | −3.0× (better) |
| Current ratio | 7.19 (better) | 3.96 |
| Altman Z-score | −3.57 | −1.79 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 15.9% |
| Held by insiders | 3.2% | 31.6% |
| Insider net buying, 12 months | −$2.3M | – |
| Short interest, % of float | 24.1% | – |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.